Caplin Point Laboratories Valuation
Is CAPLIPOINT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CAPLIPOINT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CAPLIPOINT (₹1946.1) is trading above our estimate of fair value (₹1189.06)
Significantly Below Fair Value: CAPLIPOINT is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CAPLIPOINT?
Key metric: As CAPLIPOINT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CAPLIPOINT's PE Ratio? | |
|---|---|
| PE Ratio | 25.1x |
| Earnings | ₹5.89b |
| Market Cap | ₹147.86b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.8x |
| Enterprise Value/EBITDA | 19.9x |
| PEG Ratio | 1.4x |
Price to Earnings Ratio vs Peers
How does CAPLIPOINT's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 38x | ||
NATCOPHARM NATCO Pharma | 8.7x | -41.23% | ₹147.3b |
ACUTAAS Acutaas Chemicals | 62.4x | 26.13% | ₹139.7b |
CONCORDBIO Concord Biotech | 43x | 22.59% | ₹153.1b |
530019 Jubilant Pharmova | 37.9x | 29.95% | ₹180.8b |
CAPLIPOINT Caplin Point Laboratories | 25.1x | 17.53% | ₹147.9b |
Price-To-Earnings vs Peers: CAPLIPOINT is good value based on its Price-To-Earnings Ratio (25.1x) compared to the peer average (38x).
Price to Earnings Ratio vs Industry
How does CAPLIPOINT's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 4 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 3.6x | n/a | US$94.47m |
524652 Ind-Swift | 0.3x | n/a | US$9.59m |
524661 Welcure Drugs and Pharmaceuticals | 2.9x | n/a | US$8.51m |
542724 Murae Organisor | 3.8x | n/a | US$6.50m |
| 4 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: CAPLIPOINT is good value based on its Price-To-Earnings Ratio (25.1x) compared to the Indian Pharmaceuticals industry average (29.3x).
Price to Earnings Ratio vs Fair Ratio
What is CAPLIPOINT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 25.1x |
| Fair PE Ratio | 36x |
Price-To-Earnings vs Fair Ratio: CAPLIPOINT is good value based on its Price-To-Earnings Ratio (25.1x) compared to the estimated Fair Price-To-Earnings Ratio (36x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹1,946.10 | ₹2,508.00 +28.87% | 0.32% | ₹2,516.00 | ₹2,500.00 | n/a | 2 |
| Nov ’26 | ₹2,032.80 | ₹2,508.00 +23.38% | 0.32% | ₹2,516.00 | ₹2,500.00 | n/a | 2 |
| Oct ’26 | ₹2,058.50 | ₹2,508.00 +21.84% | 0.32% | ₹2,516.00 | ₹2,500.00 | n/a | 2 |
| Sep ’26 | ₹2,109.70 | ₹2,508.00 +18.88% | 0.32% | ₹2,516.00 | ₹2,500.00 | n/a | 2 |
| Aug ’26 | ₹1,988.10 | ₹2,508.00 +26.15% | 0.32% | ₹2,516.00 | ₹2,500.00 | n/a | 2 |
| Jul ’26 | ₹1,998.20 | ₹2,508.00 +25.51% | 0.32% | ₹2,516.00 | ₹2,500.00 | n/a | 2 |
| Jun ’26 | ₹2,152.60 | ₹2,472.00 +14.84% | 2.08% | ₹2,516.00 | ₹2,400.00 | n/a | 3 |
| May ’26 | ₹1,878.90 | ₹2,472.00 +31.57% | 2.08% | ₹2,516.00 | ₹2,400.00 | n/a | 3 |
| Apr ’26 | ₹1,977.70 | ₹2,472.00 +24.99% | 2.08% | ₹2,516.00 | ₹2,400.00 | n/a | 3 |
| Mar ’26 | ₹1,822.50 | ₹2,470.00 +35.53% | 2.01% | ₹2,510.00 | ₹2,400.00 | n/a | 3 |
| Feb ’26 | ₹2,082.75 | ₹2,396.67 +15.07% | 3.92% | ₹2,510.00 | ₹2,280.00 | n/a | 3 |
| Jan ’26 | ₹2,512.30 | ₹2,396.67 -4.60% | 3.92% | ₹2,510.00 | ₹2,280.00 | n/a | 3 |
| Dec ’25 | ₹2,196.35 | ₹2,396.67 +9.12% | 3.92% | ₹2,510.00 | ₹2,280.00 | n/a | 3 |
| Nov ’25 | ₹2,024.75 | ₹2,141.67 +5.77% | 7.62% | ₹2,365.00 | ₹1,980.00 | ₹2,032.80 | 3 |
| Oct ’25 | ₹2,078.20 | ₹1,976.00 -4.92% | 4.38% | ₹2,080.00 | ₹1,868.00 | ₹2,058.50 | 3 |
| Sep ’25 | ₹1,905.00 | ₹1,882.67 -1.17% | 3.94% | ₹1,980.00 | ₹1,800.00 | ₹2,109.70 | 3 |
| Aug ’25 | ₹1,583.85 | ₹1,568.67 -0.96% | 4.16% | ₹1,660.00 | ₹1,511.00 | ₹1,988.10 | 3 |
| Jul ’25 | ₹1,452.35 | ₹1,568.67 +8.01% | 4.16% | ₹1,660.00 | ₹1,511.00 | ₹1,998.20 | 3 |
| Jun ’25 | ₹1,290.30 | ₹1,579.33 +22.40% | 3.62% | ₹1,660.00 | ₹1,535.00 | ₹2,152.60 | 3 |
| May ’25 | ₹1,356.45 | ₹1,579.33 +16.43% | 3.62% | ₹1,660.00 | ₹1,535.00 | ₹1,878.90 | 3 |
| Apr ’25 | ₹1,371.75 | ₹1,579.33 +15.13% | 3.62% | ₹1,660.00 | ₹1,535.00 | ₹1,977.70 | 3 |
| Mar ’25 | ₹1,527.05 | ₹1,601.50 +4.88% | 3.65% | ₹1,660.00 | ₹1,543.00 | ₹1,822.50 | 2 |
| Feb ’25 | ₹1,400.35 | ₹1,471.50 +5.08% | 4.86% | ₹1,543.00 | ₹1,400.00 | ₹2,082.75 | 2 |
| Jan ’25 | ₹1,355.95 | ₹1,471.50 +8.52% | 4.86% | ₹1,543.00 | ₹1,400.00 | ₹2,512.30 | 2 |
| Dec ’24 | ₹1,294.45 | ₹1,281.00 -1.04% | 21.52% | ₹1,543.00 | ₹900.00 | ₹2,196.35 | 3 |
| Nov ’24 | ₹1,020.60 | ₹996.33 -2.38% | 11.68% | ₹1,160.00 | ₹900.00 | ₹2,024.75 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/12 23:36 |
| End of Day Share Price | 2025/11/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Caplin Point Laboratories Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Siddhant Khandekar | ICICIdirect.com |